| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:MED25_MAPK15 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: MED25_MAPK15 | KinaseFusionDB ID: KFG3756 | FusionGDB2.0 ID: KFG3756 | Hgene | Tgene | Gene symbol | MED25 | MAPK15 | Gene ID | 81857 | 225689 | |
| Gene name | mediator complex subunit 25 | mitogen-activated protein kinase 15 | ||||||||||
| Synonyms | ACID1|ARC92|BVSYS|CMT2B2|P78|PTOV2|TCBAP0758 | ERK7|ERK8 | ||||||||||
| Cytomap | 19q13.33 | 8q24.3 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | mediator of RNA polymerase II transcription subunit 25ARC/mediator transcriptional coactivator subunitactivator interaction domain-containing protein 1activator-recruited cofactor 92 kDa componentmediator of RNA polymerase II transcription, subunit 25 | mitogen-activated protein kinase 15ERK-7ERK-8MAP kinase 15MAPK 15extracellular regulated kinase 8 deltaextracellular signal-regulated kinase 7extracellular signal-regulated kinase 8 | ||||||||||
| Modification date | 20240407 | 20240305 | ||||||||||
| UniProtAcc | Q9NWA0 | Q8TD08 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000312865, ENST00000538643, | ENST00000338033, ENST00000395107, ENST00000395108, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: MED25 [Title/Abstract] AND MAPK15 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MED25(50335672)-MAPK15(144799864), # samples:3 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MED25 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 17641689 |
| Tgene | MAPK15 | GO:0006974 | DNA damage response | 19166846 |
| Tgene | MAPK15 | GO:0008284 | positive regulation of cell population proliferation | 20638370 |
| Tgene | MAPK15 | GO:0010506 | regulation of autophagy | 22948227 |
| Tgene | MAPK15 | GO:0032212 | positive regulation of telomere maintenance via telomerase | 21531765 |
| Tgene | MAPK15 | GO:0046777 | protein autophosphorylation | 11875070 |
| Tgene | MAPK15 | GO:0051973 | positive regulation of telomerase activity | 21531765 |
| Tgene | MAPK15 | GO:0090494 | dopamine uptake | 28842414 |
| Tgene | MAPK15 | GO:1904355 | positive regulation of telomere capping | 21531765 |
| Kinase Fusion gene breakpoints across MED25 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Kinase Fusion gene breakpoints across MAPK15 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-OL-A66I-01A | MED25 | chr19 | 50335672 | MAPK15 | chr8 | 144799864 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:50335672/chr8:144799864) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MED25 | MAPK15 |
| FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. | FUNCTION: Atypical MAPK protein that regulates several process such as autophagy, ciliogenesis, protein trafficking/secretion and genome integrity, in a kinase activity-dependent manner (PubMed:22948227, PubMed:24618899, PubMed:29021280, PubMed:21847093, PubMed:20733054). Controls both, basal and starvation-induced autophagy throught its interaction with GABARAP, MAP1LC3B and GABARAPL1 leading to autophagosome formation, SQSTM1 degradation and reduced MAP1LC3B inhibitory phosphorylation (PubMed:22948227). Regulates primary cilium formation and the localization of ciliary proteins involved in cilium structure, transport, and signaling (PubMed:29021280). Prevents the relocation of the sugar-adding enzymes from the Golgi to the endoplasmic reticulum, thereby restricting the production of sugar-coated proteins (PubMed:24618899). Upon amino-acid starvation, mediates transitional endoplasmic reticulum site disassembly and inhibition of secretion (PubMed:21847093). Binds to chromatin leading to MAPK15 activation and interaction with PCNA, that which protects genomic integrity by inhibiting MDM2-mediated degradation of PCNA (PubMed:20733054). Regulates DA transporter (DAT) activity and protein expression via activation of RhoA (PubMed:28842414). In response to H(2)O(2) treatment phosphorylates ELAVL1, thus preventing it from binding to the PDCD4 3'UTR and rendering the PDCD4 mRNA accessible to miR-21 and leading to its degradation and loss of protein expression (PubMed:26595526). Also functions in a kinase activity-independent manner as a negative regulator of growth (By similarity). Phosphorylates in vitro FOS and MBP (PubMed:11875070, PubMed:16484222, PubMed:20638370, PubMed:19166846). During oocyte maturation, plays a key role in the microtubule organization and meiotic cell cycle progression in oocytes, fertilized eggs, and early embryos (By similarity). Interacts with ESRRA promoting its re-localization from the nucleus to the cytoplasm and then prevents its transcriptional activity (PubMed:21190936). {ECO:0000250|UniProtKB:Q80Y86, ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:11875070, ECO:0000269|PubMed:16484222, ECO:0000269|PubMed:19166846, ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:20733054, ECO:0000269|PubMed:21190936, ECO:0000269|PubMed:21847093, ECO:0000269|PubMed:22948227, ECO:0000269|PubMed:24618899, ECO:0000269|PubMed:26595526, ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of MED25_MAPK15 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | T381 | DPQLPsRtPVQGPRP | |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | Y177 | EDQAVtEyVATRWYR | Pkinase |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | S192 | APEVLLSsHRYTLGV | Pkinase |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | S331 | AHEGVQLsVPEYRSR | |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | S362 | EKGPEGVsPSQAHLH | |
| MAPK15 | Q8TD08 | human | NFKBIA | P25963 | S32 | LLDDRHDsGLDsMkD | |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | S379 | RADPQLPsRtPVQGP | |
| MAPK15 | Q8TD08 | human | NFKBIA | P25963 | S36 | RHDsGLDsMkDEEyE | |
| MAPK15 | Q8TD08 | human | JUN | P05412 | S73 | VGLLkLAsPELERLI | Jun |
| MAPK15 | Q8TD08 | human | JUN | P05412 | S63 | kNsDLLtsPDVGLLk | Jun |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | T175 | GPEDQAVtEyVATRW | Pkinase |
| MAPK15 | Q8TD08 | human | MAPK15 | Q8TD08 | T352 | ECGGSSGtSREKGPE |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAPK15 | ID | Description | 0.00e+00 |
| MAPK15 | GO:0043392 | negative regulation of DNA binding | 2.34e-03 |
| MAPK15 | GO:2000144 | positive regulation of DNA-templated transcription initiation | 3.51e-03 |
| MAPK15 | GO:2000142 | regulation of DNA-templated transcription initiation | 3.51e-03 |
| MAPK15 | GO:0051101 | regulation of DNA binding | 3.51e-03 |
| MAPK15 | GO:0051100 | negative regulation of binding | 5.70e-03 |
| MAPK15 | GO:0006352 | DNA-templated transcription initiation | 7.70e-03 |
| MAPK15 | GO:0051098 | regulation of binding | 1.91e-02 |
| MAPK15 | GO:0015850 | organic hydroxy compound transport | 2.31e-02 |
| MAPK15 | GO:1901993 | regulation of meiotic cell cycle phase transition | 3.09e-02 |
| MAPK15 | GO:0044771 | meiotic cell cycle phase transition | 3.09e-02 |
| MAPK15 | GO:0070417 | cellular response to cold | 3.09e-02 |
| MAPK15 | GO:0010745 | negative regulation of macrophage derived foam cell differentiation | 3.09e-02 |
| MAPK15 | GO:0042994 | cytoplasmic sequestering of transcription factor | 3.09e-02 |
| MAPK15 | GO:0043922 | negative regulation by host of viral transcription | 3.09e-02 |
| MAPK15 | GO:1902101 | positive regulation of metaphase/anaphase transition of cell cycle | 3.09e-02 |
| MAPK15 | GO:0043923 | positive regulation by host of viral transcription | 3.09e-02 |
| MAPK15 | GO:0090494 | dopamine uptake | 3.09e-02 |
| MAPK15 | GO:1904355 | positive regulation of telomere capping | 3.09e-02 |
| MAPK15 | GO:0090493 | catecholamine uptake | 3.09e-02 |
| MAPK15 | GO:0070431 | nucleotide-binding oligomerization domain containing 2 signaling pathway | 3.09e-02 |
| MAPK15 | GO:0032495 | response to muramyl dipeptide | 3.09e-02 |
| MAPK15 | GO:0010888 | negative regulation of lipid storage | 3.09e-02 |
| MAPK15 | GO:0051220 | cytoplasmic sequestering of protein | 3.09e-02 |
| MAPK15 | GO:0035994 | response to muscle stretch | 3.09e-02 |
| MAPK15 | GO:1904353 | regulation of telomere capping | 3.09e-02 |
| MAPK15 | GO:0010875 | positive regulation of cholesterol efflux | 3.09e-02 |
| MAPK15 | GO:0048207 | vesicle targetin | 4.29e-03 |
| MAPK15 | GO:0051446 | positive regulation of meiotic cell cycle | 3.09e-02 |
| MAPK15 | GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 3.09e-02 |
| MAPK15 | GO:0035872 | nucleotide-binding domai | 4.60e-03 |
| MAPK15 | GO:0070498 | interleukin-1-mediated signaling pathway | 3.09e-02 |
| MAPK15 | GO:0090169 | regulation of spindle assembly | 3.09e-02 |
| MAPK15 | GO:0010743 | regulation of macrophage derived foam cell differentiation | 3.09e-02 |
| MAPK15 | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 3.09e-02 |
| MAPK15 | GO:0032212 | positive regulation of telomere maintenance via telomerase | 3.09e-02 |
| MAPK15 | GO:0048199 | vesicle targetin | 3.40e+01 |
| MAPK15 | GO:0071276 | cellular response to cadmium ion | 3.09e-02 |
| MAPK15 | GO:1904358 | positive regulation of telomere maintenance via telomere lengthening | 3.09e-02 |
| MAPK15 | GO:0032373 | positive regulation of sterol transport | 3.09e-02 |
| MAPK15 | GO:0032376 | positive regulation of cholesterol transport | 3.09e-02 |
| MAPK15 | GO:0016233 | telomere capping | 3.09e-02 |
| MAPK15 | GO:0043620 | regulation of DNA-templated transcription in response to stress | 3.09e-02 |
| MAPK15 | GO:0045746 | negative regulation of Notch signaling pathway | 3.09e-02 |
| MAPK15 | GO:0006901 | vesicle coating | 3.09e-02 |
| MAPK15 | GO:0010742 | macrophage derived foam cell differentiation | 3.09e-02 |
| MAPK15 | GO:0090077 | foam cell differentiation | 3.11e-02 |
| MAPK15 | GO:0140467 | integrated stress response signaling | 3.12e-02 |
| MAPK15 | GO:0009409 | response to cold | 3.14e-02 |
| MAPK15 | GO:0090114 | COPII-coated vesicle budding | 3.14e-02 |
Top |
Related Drugs to MED25_MAPK15 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning MED25-MAPK15 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to MED25_MAPK15 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |